Investors & Media

Corporate Profile

NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need. Today, the company has four programs in active clinical development.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News & Events

News Releases

April 5, 2024

NGM Bio Announces Closing of Tender Offer

March 19, 2024

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting

March 11, 2024

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

Events

October 17, 2022 at 5:00 AM PDT

June 29, 2022 from 11:00 AM to 12:30 PM EDT

Contact Information

investor relations

ir@ngmbio.com

media relations

media@ngmbio.com